tirzepatide surmount-1 weight loss percent 72 weeks results Trial SURMOUNT-1: Adults achieve weight loss

GLP-1 receptor activation stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central appetite regulation

This corresponded to a risk difference of 0.3% (95% CI 0.4% to 0.1%) and a hazard ratio of 0.82 (95% CI 0.74 to 0.91) (Fig

What the data does support is a reasonable clinical rationale for trying a dual agonist when a single-pathway drug hasn't delivered

The timing principles that apply to semaglutide also apply to tirzepatide

How should I choose between a dual agonist and a triple agonist

Gallbladder problems: Gallbladder problems have happened in some people who use Tirzepatide